Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - RESOLUTE ONCOLOGY INCFinancial_Report.xls
EX-14.1 - CODE OF BUSINESS CONDUCT AND ETHICS - RESOLUTE ONCOLOGY INCex141k123112.htm
EX-10.2 - BRIDGE LOAN AGREEMENT DATED NOVEMBER 1, 2012 - RESOLUTE ONCOLOGY INCex102k123112.htm
EX-10.4 - BRIDGE LOAN AGREEMENT WITH GEN BIOPHARMA INC. DATED DECEMBER 31, 2012 - RESOLUTE ONCOLOGY INCex104k123112.htm
EX-10.3 - PROMISSORY NOTE WITH GEN BIOPHARMA INC. DATED DECEMBER 31, 2012 - RESOLUTE ONCOLOGY INCex103k123112.htm
10-K - FORM 10-K YEAR ENDED DECEMBER 31, 2012 - RESOLUTE ONCOLOGY INCk123112.htm
EX-31.1 - CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 OF THE PRINCIPAL EXECUTIVE OFFICER, PRINCIPAL FINANCIAL OFFICER AND PRINCIPAL ACCOUNTING OFFICER - RESOLUTE ONCOLOGY INCex311k123112.htm
EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Blair Sorby, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)
the Annual Report on Form 10-K of Resolute Oncology Inc. for the year ended December 31, 2012 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Resolute Oncology Inc.
 

 
Dated: March 28, 2013
Resolute Oncology Inc.
   
   
 
/s/ Blair Sorby
 
Blair Sorby
 
President, Chief Executive Officer, Chief Financial Officer, Secretary,
Treasurer and Director (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)


A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Resolute Oncology Inc. and will be retained by Resolute Oncology Inc. and furnished to the Securities and Exchange Commission or its staff upon request.